New uses of abobotulinumtoxina in aesthetics

Joel Schlessinger, Erin Gilbert, Joel L. Cohen, Joely Kaufman

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

BotulinumtoxinA (BoNT-A) is now widely established for the main approved indication of reducing glabellar lines, and is also widely used off-label to improve the appearance of wrinkles and lines in other parts of the face. The number of aesthetic procedures continues to increase as the patient population becomes more diverse, in particular with increasing numbers of people of color and men. Further developments in treatment may continue to expand the audience for BoNT-A by making procedures more comfortable and by delivering a more natural, less static appearance. These may be achieved through use of combinations of BoNT-A with other aesthetic procedures, tailoring the dose of toxin to the patient's muscle mass or by using novel injection and application techniques. Beyond amelioration of facial lines, encouraging results have been seen with the use of BoNT-A to improve the appearance of hypertrophic and keloid scars and even to prevent them. Studies have been conducted with scars in various parts of the body and further research is ongoing. Dermatological and other medical uses for BoNT-A are also active areas of research. Injections of BoNT-A have been shown to reduce signs and symptoms of acne, rosacea, and psoriasis, to reduce neuromuscular pain, and to bring about significant improvements in a number of rare diseases that are caused or exacerbated by hyperhidrosis. This paper reviews these new uses for BoNT-A, looking at the rationale for their use and discussing the results of published case studies and clinical trials. These areas have shown great promise to date, but more and larger clinical studies will be required before these treatments become a clinical reality. To this end details are also provided of clinical trials currently listed in the main clinical trials database to highlight research areas of particular interest.

Original languageEnglish (US)
Pages (from-to)S45-S58
JournalAesthetic Surgery Journal
Volume37
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Esthetics
Clinical Trials
Research
Rosacea
Hypertrophic Cicatrix
Hyperhidrosis
Keloid
Injections
Rare Diseases
incobotulinumtoxinA
abobotulinumtoxinA
Human Body
Psoriasis
Signs and Symptoms
Cicatrix
Color
Databases
Pain
Muscles
Therapeutics

ASJC Scopus subject areas

  • Surgery

Cite this

Schlessinger, J., Gilbert, E., Cohen, J. L., & Kaufman, J. (2017). New uses of abobotulinumtoxina in aesthetics. Aesthetic Surgery Journal, 37, S45-S58. https://doi.org/10.1093/asj/sjx005

New uses of abobotulinumtoxina in aesthetics. / Schlessinger, Joel; Gilbert, Erin; Cohen, Joel L.; Kaufman, Joely.

In: Aesthetic Surgery Journal, Vol. 37, 01.01.2017, p. S45-S58.

Research output: Contribution to journalArticle

Schlessinger, J, Gilbert, E, Cohen, JL & Kaufman, J 2017, 'New uses of abobotulinumtoxina in aesthetics', Aesthetic Surgery Journal, vol. 37, pp. S45-S58. https://doi.org/10.1093/asj/sjx005
Schlessinger J, Gilbert E, Cohen JL, Kaufman J. New uses of abobotulinumtoxina in aesthetics. Aesthetic Surgery Journal. 2017 Jan 1;37:S45-S58. https://doi.org/10.1093/asj/sjx005
Schlessinger, Joel ; Gilbert, Erin ; Cohen, Joel L. ; Kaufman, Joely. / New uses of abobotulinumtoxina in aesthetics. In: Aesthetic Surgery Journal. 2017 ; Vol. 37. pp. S45-S58.
@article{18c04e763d004a4595ef1a5038f74b91,
title = "New uses of abobotulinumtoxina in aesthetics",
abstract = "BotulinumtoxinA (BoNT-A) is now widely established for the main approved indication of reducing glabellar lines, and is also widely used off-label to improve the appearance of wrinkles and lines in other parts of the face. The number of aesthetic procedures continues to increase as the patient population becomes more diverse, in particular with increasing numbers of people of color and men. Further developments in treatment may continue to expand the audience for BoNT-A by making procedures more comfortable and by delivering a more natural, less static appearance. These may be achieved through use of combinations of BoNT-A with other aesthetic procedures, tailoring the dose of toxin to the patient's muscle mass or by using novel injection and application techniques. Beyond amelioration of facial lines, encouraging results have been seen with the use of BoNT-A to improve the appearance of hypertrophic and keloid scars and even to prevent them. Studies have been conducted with scars in various parts of the body and further research is ongoing. Dermatological and other medical uses for BoNT-A are also active areas of research. Injections of BoNT-A have been shown to reduce signs and symptoms of acne, rosacea, and psoriasis, to reduce neuromuscular pain, and to bring about significant improvements in a number of rare diseases that are caused or exacerbated by hyperhidrosis. This paper reviews these new uses for BoNT-A, looking at the rationale for their use and discussing the results of published case studies and clinical trials. These areas have shown great promise to date, but more and larger clinical studies will be required before these treatments become a clinical reality. To this end details are also provided of clinical trials currently listed in the main clinical trials database to highlight research areas of particular interest.",
author = "Joel Schlessinger and Erin Gilbert and Cohen, {Joel L.} and Joely Kaufman",
year = "2017",
month = "1",
day = "1",
doi = "10.1093/asj/sjx005",
language = "English (US)",
volume = "37",
pages = "S45--S58",
journal = "Aesthetic Surgery Journal",
issn = "1090-820X",
publisher = "SAGE Publications Inc.",

}

TY - JOUR

T1 - New uses of abobotulinumtoxina in aesthetics

AU - Schlessinger, Joel

AU - Gilbert, Erin

AU - Cohen, Joel L.

AU - Kaufman, Joely

PY - 2017/1/1

Y1 - 2017/1/1

N2 - BotulinumtoxinA (BoNT-A) is now widely established for the main approved indication of reducing glabellar lines, and is also widely used off-label to improve the appearance of wrinkles and lines in other parts of the face. The number of aesthetic procedures continues to increase as the patient population becomes more diverse, in particular with increasing numbers of people of color and men. Further developments in treatment may continue to expand the audience for BoNT-A by making procedures more comfortable and by delivering a more natural, less static appearance. These may be achieved through use of combinations of BoNT-A with other aesthetic procedures, tailoring the dose of toxin to the patient's muscle mass or by using novel injection and application techniques. Beyond amelioration of facial lines, encouraging results have been seen with the use of BoNT-A to improve the appearance of hypertrophic and keloid scars and even to prevent them. Studies have been conducted with scars in various parts of the body and further research is ongoing. Dermatological and other medical uses for BoNT-A are also active areas of research. Injections of BoNT-A have been shown to reduce signs and symptoms of acne, rosacea, and psoriasis, to reduce neuromuscular pain, and to bring about significant improvements in a number of rare diseases that are caused or exacerbated by hyperhidrosis. This paper reviews these new uses for BoNT-A, looking at the rationale for their use and discussing the results of published case studies and clinical trials. These areas have shown great promise to date, but more and larger clinical studies will be required before these treatments become a clinical reality. To this end details are also provided of clinical trials currently listed in the main clinical trials database to highlight research areas of particular interest.

AB - BotulinumtoxinA (BoNT-A) is now widely established for the main approved indication of reducing glabellar lines, and is also widely used off-label to improve the appearance of wrinkles and lines in other parts of the face. The number of aesthetic procedures continues to increase as the patient population becomes more diverse, in particular with increasing numbers of people of color and men. Further developments in treatment may continue to expand the audience for BoNT-A by making procedures more comfortable and by delivering a more natural, less static appearance. These may be achieved through use of combinations of BoNT-A with other aesthetic procedures, tailoring the dose of toxin to the patient's muscle mass or by using novel injection and application techniques. Beyond amelioration of facial lines, encouraging results have been seen with the use of BoNT-A to improve the appearance of hypertrophic and keloid scars and even to prevent them. Studies have been conducted with scars in various parts of the body and further research is ongoing. Dermatological and other medical uses for BoNT-A are also active areas of research. Injections of BoNT-A have been shown to reduce signs and symptoms of acne, rosacea, and psoriasis, to reduce neuromuscular pain, and to bring about significant improvements in a number of rare diseases that are caused or exacerbated by hyperhidrosis. This paper reviews these new uses for BoNT-A, looking at the rationale for their use and discussing the results of published case studies and clinical trials. These areas have shown great promise to date, but more and larger clinical studies will be required before these treatments become a clinical reality. To this end details are also provided of clinical trials currently listed in the main clinical trials database to highlight research areas of particular interest.

UR - http://www.scopus.com/inward/record.url?scp=85021857660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021857660&partnerID=8YFLogxK

U2 - 10.1093/asj/sjx005

DO - 10.1093/asj/sjx005

M3 - Article

C2 - 28388720

AN - SCOPUS:85021857660

VL - 37

SP - S45-S58

JO - Aesthetic Surgery Journal

JF - Aesthetic Surgery Journal

SN - 1090-820X

ER -